How does TANOVEA-CA1 work?

TANOVEA-CA1 is the first lymphoma treatment for dogs that has been conditionally approved by the FDA. Targeting rapidly multiplying lymphoma cells, it mimics a DNA building block, preventing cells from dividing and ultimately causing them to die. The medication is … Keep Reading

VetDC achieves key regulatory milestone, nears FDA approval of TANOVEA™-CA1 for Canine Lymphoma

FORT COLLINS, Colo.–(BUSINESS WIRE)–VetDC, Inc., a veterinary cancer therapeutics company, today announced that the Company has received three major technical section complete letters for TANOVEA™-CA1 (rabacfosadine) from the U.S. Food and Drug Administration’s Center for Veterinary Medicine (FDA-CVM). Upon approval, … Keep Reading